Introduction
============

Adenosine triphosphate-binding cassette sub-family G member 2 (ABCG2) performs certain physiological functions *in vivo*, such as maintaining cell homeostasis ([@B32]), the blood-brain barrier ([@B7]; [@B9]), disease susceptibility ([@B26]), and pharmacokinetics ([@B16]). Additionally, studies have reported that it has an effect on multi-drug resistance of chemotherapeutic agents, such as mitoxantrone and camptothecin analogues ([@B35], [@B23]). Previous studies have suggested that several naturally occurring single-nucleotide polymorphisms (SNPs, variations in a single nucleotide at a specific position in the genome), in the ABCG2 gene may affect the expression and function of ABCG2 protein ([@B13]; [@B18]). More than 80 SNPs have been identified in the *ABCG2* gene ([@B30]). Specifically, ABCG2 polymorphism caused by the 421 locus change in the fifth exon could lead to a decrease in ABCG2 protein expression, which in turn affects the removal and absorption of pravastatin ([@B24]) and simvastatin ([@B36]). [@B5] have indicated that the ABCG2 421C\>A (rs2231142) polymorphism, resulting in a Glu141Lys substitution, is a protective factor for developing cancer. Additionally, ABCG2 34G\>A (rs2231137), resulting in a Val12Met substitution, is also well studied and is related to the adverse effect of many drugs that are transported by ABCG2 ([@B12]).

Lung cancer is the leading cause of cancer-related deaths worldwide, and approximately 85% of lung cancers are non-small cell lung cancer (NSCLC) ([@B1]). Chemotherapy is a common choice for NSCLC treatment ([@B29]; [@B27]), while chemoresistance is a challenge during the treatment ([@B4]). As mentioned above, SNPs in ABCG2 can affect the expression of ABCG2 protein. ABCG2 protein expression is reported to be related to the response of advanced NSCLC patients treated with chemotherapy ([@B25]). Some studies have focused on investigating the relationships between *ABCG2* gene polymorphism and treatment effects of chemotherapy on NSCLC patients, however no consensus has been reached ([@B8]; [@B11]; [@B2]; [@B19]; [@B17]; [@B3]; [@B21]; [@B10]; [@B14]; [@B6]). [@B33] suggest that ABCG2 34G\>A would be useful in predicting a worsening of skin rash. [@B17] did not find any significant association between the evaluated ABCG2 polymorphisms and response, clinical benefit, time to progression (TTP), or overall survival (OS). Moreover, due to the small sample sizes of the individual studies, there is a need to perform a meta-analysis to combine them and systematically analyze the relationships between *ABCG2* gene polymorphism and treatment effects among NSCLC patients.[@B28]

Therefore, this study aims to explore the prognosis value of *ABCG2* gene polymorphism on the chemotherapy effect of NSCLC through a systematic review of studies and meta-analysis.

Material and Methods
====================

Data sources
------------

The search strategy was pre-designed. The databases PubMed and EMBASE were searched for studies on *ABCG2* gene polymorphism and NSCLC outcomes published before December 3, 2018. The keywords included: \['non-small cell lung cancer' OR 'NSCLC' OR 'squamous cell lung cancer' OR 'lung adenocarcinoma' OR 'large cell lung cancer'\] AND \['ATP-binding cassette sub-family G member 2' OR 'ABCG2' OR 'breast cancer resistance protein' OR 'BCRP' OR 'CDw338' OR 'mitoxantrone resistance protein' OR 'MRP' OR 'ABCP'\] AND \['polymorphism' OR 'polymorphisms' OR 'genetic' OR 'variation' OR 'genotyping' OR 'SNP'\].

Inclusion criteria and quality assessment
-----------------------------------------

The inclusion criteria were 1) clinical studies with NSCLC patients as cases; 2) studies that investigated the correlation between *ABCG2* gene polymorphisms and NSCLC treatment effects; 3) studies that reported the frequencies of gene types and alleles or from which these data can be calculated; 4) studies that reported curative effect indicators such as progression free survival (PFS), overall survival (OS), mortality risk, and response; and adverse effect indicators such as drug-induced diarrhea, skin toxicity, liver dysfunction, and interstitial pneumonia; 5) reviews, reports, comments or letters were excluded. Newcastle-Ottawa Scale (NOS) ([@B31]) was used for quality assessment.

Data extraction
---------------

The following data from the included studies was extracted independently by two researchers, including first author, publication year, distribution of ethnic groups, distribution and frequencies of genotypes and alleles, and the gender and age of patients in each study. If there was inconsistency during data extraction, discussion with a third researcher was initiated until an agreement was reached.

Statistical analysis
--------------------

Meta-analysis was conducted using the Review Manager Version 5.3 (2008). Mortality risk was combined using HR and 95% *CI*. *RR* and 95% *CI*s (m (mutation)/m + w (wild)/m vs. w/w) were used to calculate the combined effect sizes of the other indicators. Heterogeneity test was conducted according to the chi-square-based *Q* test ([@B15]) and *I*^2^ statistic. If there was significant heterogeneity (*P* \< 0.05, *I*^2^ \> 50%), the random-effect model (by Dersimonian-Laird method) was used to pool the effect sizes; otherwise, the FE model (by Mantel-Haenszel method) was used. Subgroup meta-analysis based on chemotherapeutics, race, and grade of toxicity was performed. Begg's test and Egger's test were used to examine publication bias for studies with the largest number of publications included. All tests were two-sided, with a significance threshold of *P* \< 0.05.

Results
=======

Study selection and the characteristics of correlational studies
----------------------------------------------------------------

[Figure 1](#f1){ref-type="fig"} shows the study selection procedure. Firstly, a total of 722 studies (123 in PubMed and 599 in EMBASE) were searched. After removal of duplicates or irrelevant studies, 63 studies remained for reading of the full text and abstract. Of these, 10 reviews and 20 cell experiments, 16 non-NSCLC related studies and three without extractable data were rejected, leaving 14 studies. Additionally, two studies without data associated with 34 G\>A and 421 C\>A, and two studies without the correlation between ABCG2 polymorphism and efficacy and side effects of chemotherapy were excluded. Finally, a total of 10 studies ([@B8]; [@B11]; [@B22]; [@B2]; [@B17]; [@B33]; [@B10]; [@B7]; [@B13]; [@B20]) were included in this meta-analysis.[@B3] [@B4]

![Flow chart of literature search and study selection.](1415-4757-GMB-42-4-e20180234-gf01){#f1}

The characteristics of correlational studies are listed in [Table 1](#t1){ref-type="table"}. These studies were mainly conducted in China, Japan, Germany, Italy, and Korea. The patients mainly were at stages III--IV. The chemotherapy regimens included Etoposide + Gemcitabine + Platinum-based drugs, Gefitinib and Erlotinib. The studies had relatively high-quality scores of 5--7 ([Table 2](#t2){ref-type="table"}).

###### Characteristics of the included studies.

  Author      Year   Area (race)           No. of patients   Chemotherapy regimen                         Stage     Evaluation criteria
  ----------- ------ --------------------- ----------------- -------------------------------------------- --------- ---------------------
  Akasaka     2010   Japan (Asian)         75                Gefitinib                                    I-IV      WHO
  Chen        2015   China (Asian)         70                gefitinib, erlotinib and icotinib            I-II      ECOG
  Cusatis     2006   Italy (Caucasian)     173               Gefitinib                                    I-IV      WHO
  Fukudo      2013   Japan (Asian)         88                Erlotinib                                    IIIB-IV   ECOG
  Han         2007   Korea (Asian)         107               Irinotecan and cisplatin                     IIIB-IV   ECOG
  Kobayashi   2014   Japan (Asian)         31                Gefitinib                                    IIIB-IV   CTCAE
  Lemos       2011   Italy (Caucasian)     94                Gefitinib                                    IIIB-IV   ECOG
  Ma          2017   China (Asian)         59                Gefitinib                                    IIIB-IV   ECOG
  Muller      2009   Germany (Caucasian)   187               Etoposide+Gemcitabine+Platinum-based drugs   II-IV     RECIST
  Tamura      2012   Japan (Asian)         83                Gefitinib                                    I-IV      CTCAE

WHO, World Health Organization; ECOG, Eastern Cooperative Oncology Group; CTCAE, Common Terminology Criteria For Adverse Events; RECIST, Response Evaluation Criteria In Solid Tumors.

###### Quality assessment of the included studies with Newcastle-Ottawa quality assessment scale.

  First author     Representativeness of the exposed cohort   Selection of the unexposed cohort   Ascertainment of exposure   Outcome of interest not present at start of study   Control for important factor or additional factor   Outcome assessment   Follow-up long enough for outcomes to occur   Adequacy of follow-up of cohorts   Total quality scores
  ---------------- ------------------------------------------ ----------------------------------- --------------------------- --------------------------------------------------- --------------------------------------------------- -------------------- --------------------------------------------- ---------------------------------- ----------------------
  Akasaka 2010     \#                                         \--                                 \#                          \#                                                  \--                                                 \#                   \#                                            \#                                 6
  Chen 2015        \#                                         \--                                 \#                          \#                                                  \#                                                  \#                   \#                                            \#                                 7
  Cusatis 2006     \#                                         \--                                 \#                          \#                                                  \--                                                 \#                   \--                                           \#                                 5
  Fukudo 2013      \#                                         \--                                 \#                          \#                                                  \#                                                  \#                   \#                                            \#                                 7
  Han 2007         \#                                         \--                                 \#                          \#                                                  \--                                                 \#                   \#                                            \#                                 6
  Kobayashi 2015   \#                                         \--                                 \#                          \--                                                 \#                                                  \#                   \#                                            \#                                 6
  Lemos 2011       \#                                         \--                                 \#                          \#                                                  \#                                                  \#                   \#                                            \#                                 7
  Ma 2017          \#                                         \--                                 \#                          \#                                                  \--                                                 \#                   \#                                            \#                                 6
  Muller 2009      \#                                         \--                                 \#                          \#                                                  \#                                                  \#                   \#                                            \#                                 7
  Tamura 2012      \#                                         \--                                 \#                          \#                                                  \--                                                 \#                   \#                                            \#                                 6

Correlation between *ABCG2* gene polymorphism and treatment effect of NSCLC
---------------------------------------------------------------------------

The correlations between the polymorphisms of two loci of the *ABCG2* gene and the prognosis of chemotherapy for NSCLC were investigated. The results are displayed in Figures S1 -S8. For the indicators of OS, PFS, mortality (Figures S1 -S3), and interstitial pneumonia (Figure S8), the included literature only report the data related to ABCG2 421C\>A. There were no heterogeneities among studies for all curative effect indicators and adverse effect indicators (*P* \> 0.05, *I*^*2*^ \> 50%), thus the FE model was adopted to combine all effect sizes. The meta-analysis results show that the polymorphism ABCG2 421C\>A had no relationship with outcomes of chemotherapy for NSCLC (*P* \> 0.05), and ABCG2 34G\>A was significantly correlated with skin toxicity (*P* \< 0.05) (Figures S1 -S8).

Subgroup analysis
-----------------

Subgroup analysis of skin toxicity and diarrhea of 421 loci CC/(AC + AA) based on the chemotherapeutics (gefitinib *vs.* others), races (Asian *vs.* Caucasian) and grade of toxicity (Grade f 1 vs. 0, Grade y 2 vs. Grade \< 2) were performed. The results show that ABCG2 421C\>A had no influence on skin toxicity or diarrhea (*P* \> 0.05, [Table 3](#t3){ref-type="table"}).

###### Subgroup analyses of ABCG2 421C\>A (AA+CA vs. CC).

  Subgroups                                                     Adverse events   *P* ~value~         Test for heterogeneity         
  ------------------------------------------------------------- ---------------- ------------------- ------------------------ ----- ------
  **Association between ABCG2 421C**\>A **and skin toxicity**                                                                       
  **Race**                                                                                                                          
  Asian                                                         5                0.88 (0.74, 1.05)   0.17                     0%    0.81
  Caucasian                                                     2                0.99 (0.78, 1.25)   0.95                     0%    0.54
  **Chemotherapy regimen**                                                                                                          
  Gefitinib                                                     6                0.89 (0.77, 1.04)   0.16                     0%    0.71
  Others                                                        1                1.00 (0.68, 1.48)   0.98                     \--   \--
  **Grade of toxicity**                                                                                                             
  Grade ≥                                                       5                0.91 (0.78, 1.06)   0.23                     0%    0.64
  Grade(0                                                       2                0.92 (0.65, 1.30)   0.63                     0%    0.49
  **Association between ABCG2 421C**\>A **and diarrhea**                                                                            
  **Race**                                                                                                                          
  Asian                                                         6                0.99 (0.70, 1.38)   0.93                     22%   0.27
  Caucasian                                                     2                0.82 (0.60, 1.12)   0.22                     0%    0.43
  **Chemotherapy regimen**                                                                                                          
  Gefitinib                                                     6                0.80 (0.62, 1.02)   0.07                     0%    0.97
  Others                                                        2                1.69 (0.86, 3.33)   0.13                     48%   0.16
  **Grade of toxicity**                                                                                                             
  Gradeto                                                       5                0.81 (0.63, 1.04)   0.10                     0%    0.93
  Grade63                                                       3                1.44 (0.76, 2.71)   0.26                     43%   0.17

Publication bias
----------------

The publication bias test was conducted on "drug-induced diarrhea" of ABCG2 421C\>A that had the most included papers. Both Begg's test and Egger's test indicated that no publication bias exists (Begg's test: *P* = 0.386, Egger's test: *P* = 0.834).

Discussion
==========

This meta-analysis systematically reviewed *ABCG2* gene polymorphisms and the efficacy and safety of NSCLC treatment. Polymorphisms at two loci of the *ABCG2* gene (34 G\>A and 421 C\>A) were evaluated. In addition, the qualities of the included studies are relatively high. There is no significant heterogeneity among studies for the entire analysis. Moreover, no publication bias is noted. Furthermore, compared with a recent meta-analysis of [@B34], which determined whether *ABCG2* gene polymorphisms are associated with the risk of gefitinib-induced toxicity in NSCLC patients, our study added meta-analysis of survival outcomes.

Overall, this meta-analysis did not find a significant relationship between evaluated *ABCG2* gene polymorphisms and the curative effects and adverse effects of chemotherapy of NSCLC, except that ABCG2 34G\>A showed a negative relationship with skin toxicity in patients after chemotherapy. However there was only one study ([@B21]) on 34G\>A, which might have resulted in insufficient power. More studies on 34G\>A should be performed.

ABCG2 may have an effect on the multi-drug resistance of chemotherapeutic agents such as mitoxantrone and camptothecin analogues ([@B23]; [@B35]). However, for the NSCLC patients, cisplatin (59.73%) and carboplatin (30.20%) are mostly used ([@B27]). In the studies included in this meta-analysis, gefitinib is the most widely used, followed by etoposide. Drug resistance to gefitinib and etoposide was not noted. Subgroup analysis based on different chemotherapeutics was performed. There was no significant relationship between the polymorphisms on 421C\>A and skin toxicity or diarrhea after treatment for gefitinib or other drugs. Similarly, there were no differences between Asians and Caucasians in the relationship.

This meta-analysis did not limit the types of chemotherapy drugs and included as many studies as possible. Additionally, we added the analysis of survival outcomes. Nevertheless, there were shortcomings in this study, due to the small sample size for some indices, and conclusions from the results should therefore be drawn with caution.

In all, it can be concluded that the ABCG2 polymorphism could not be used as a prognosis indicator of chemotherapy for NSCLC. However, due to the limitations in this study, the results should be interpreted cautiously. More studies with large sample sizes, randomized designs, and unified styles of outcomes are necessary.
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